No Data
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
ZyVersa Therapeutics Q3 2024 GAAP EPS $(2.43) Beats $(3.70) Estimate
Express News | Zyversa Therapeutics - Qtrly Loss per Share $2.43
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Press Release: ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Express News | Zyversa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
No Data
No Data